Liquidia (NASDAQ:LQDA) Insider Jason Adair Sells 688 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Jason Adair sold 688 shares of the company’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $87.53, for a total value of $60,220.64. Following the sale, the insider directly owned 216,438 shares in the company, valued at $18,944,818.14. This trade represents a 0.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jason Adair also recently made the following trade(s):

• On Monday, July 13th, Jason Adair sold 7,863 shares of Liquidia stock. The stock was sold at an average price of $71.51, for a total transaction of $562,283.13.

Liquidia Price Performance

Liquidia stock opened at $86.82 on Thursday. The company has a market cap of $7.72 billion, a price-to-earnings ratio of 620.19 and a beta of 0.55. The firm’s fifty day moving average is $72.81 and its 200 day moving average is $51.36. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. Liquidia Corporation has a 52-week low of $16.82 and a 52-week high of $91.10.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings data on Monday, May 11th. The company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The business had revenue of $132.87 million during the quarter, compared to analyst estimates of $119.44 million. The business’s revenue for the quarter was up 4187.1% compared to the same quarter last year. Sell-side analysts forecast that Liquidia Corporation will post 3.02 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on LQDA. HC Wainwright set a $36.00 price target on Liquidia in a research report on Friday, July 24th. Wells Fargo & Company upped their price objective on Liquidia from $51.00 to $62.00 and gave the company an “overweight” rating in a research report on Tuesday, May 12th. Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 5th. Jefferies Financial Group reissued a “buy” rating and set a $60.00 target price on shares of Liquidia in a research report on Monday, May 11th. Finally, Raymond James Financial restated a “strong-buy” rating and set a $68.00 price target on shares of Liquidia in a report on Thursday, June 4th. Three investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.18.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of LQDA. Farallon Capital Management LLC raised its holdings in shares of Liquidia by 1.1% in the fourth quarter. Farallon Capital Management LLC now owns 8,656,038 shares of the company’s stock worth $298,547,000 after buying an additional 90,400 shares during the period. Vanguard Group Inc. lifted its position in shares of Liquidia by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 4,013,888 shares of the company’s stock worth $138,439,000 after purchasing an additional 52,671 shares during the last quarter. Opaleye Management Inc. boosted its stake in shares of Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock valued at $30,838,000 after purchasing an additional 215,000 shares during the period. Bank of America Corp DE boosted its stake in shares of Liquidia by 18.7% during the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares during the period. Finally, Caprock Group LLC grew its holdings in shares of Liquidia by 9.3% in the fourth quarter. Caprock Group LLC now owns 1,783,921 shares of the company’s stock worth $61,527,000 after purchasing an additional 151,832 shares during the last quarter. Institutional investors own 64.54% of the company’s stock.

Key Stories Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia will report its second-quarter 2026 financial results on August 12, 2026. The update should provide investors with insight into YUTREPIA sales, operating performance and the company’s outlook. Liquidia Second Quarter 2026 Results Announcement
• Positive Sentiment: LifeSci Capital maintained a Buy rating, while Buckley Capital Advisors cited potential upside of more than 50% based on a prospective YUTREPIA ruling and possible buyout interest. These views support the bullish case, although they depend on regulatory and strategic outcomes. LifeSci Capital Buy Rating Buckley Capital Liquidia Investor Letter
• Neutral Sentiment: Recent coverage highlights a valuation debate: YUTREPIA could drive substantial growth, but patent risks and the stock’s elevated valuation may limit further gains. Shares trade at roughly 620 times earnings, making execution especially important.
• Negative Sentiment: Several insiders reported sales. Director Stephen Bloch sold 178,596 shares for about $15.2 million across July 20–23, while Jason Adair and Chief Accounting Officer Dana Boyle sold smaller amounts on July 27. The latter transactions were conducted under Rule 10b5-1 plans to cover tax withholding, reducing their negative significance; nevertheless, the director’s larger sales may encourage profit-taking concerns. Liquidia Insider Sales SEC Filing

About Liquidia

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).